K562/GM-CSF Vaccination in Patients With Myelodysplastic Syndrome.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs GM-CSF-transduced tumour cell vaccine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2018 Biomarkers information updated
- 01 Oct 2010 Planned end date changed from Jan 2009 to Dec 2012 as reported by ClinicalTrials.gov.
- 24 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.